Innophore
Innophore provides computational drug discovery and enzyme engineering through its Catalophore™ technology, which represents protein binding sites as 3D point clouds of physico-chemical properties for proteome-wide similarity searching. The platform is available as research services, on-premise software (Catalophore Pro), and cloud-based tools like CavitOmiX, with GPU acceleration enabling up to five million off-target predictions per second.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Software Only
- Healthcare Technology
Funding
Funding not disclosed
across 1 round
Founders
Founder details are not available yet.
Product
Problem
Traditional computational drug discovery and enzyme engineering rely heavily on sequence and fold comparisons, which miss functional similarities between proteins that share little primary or tertiary structure. This limits the ability to identify off-target effects, repurpose existing drugs, or find novel biocatalysts, leading to costly late-stage failures and missed opportunities in the lab.
Solution
Innophore offers a computational discovery platform built on Catalophore™, a proprietary technology that represents every protein cavity as a 3D point cloud with physico-chemical property channels. This allows researchers to search across entire proteomes for binding sites that match by shape, hydrophobicity, electrostatics, and other properties, independent of sequence or fold. The platform supports multiple workflows, including hit identification, drug repurposing, off-target screening, and biocatalysis, all within a single unified workbench. It is delivered through several products: Catalophore Pro, an on-premise platform for managing molecular libraries; CavitOmiX, a cloud-based copilot for off-target search; and a PyMOL plugin for direct integration into existing visualization tools. The technology is GPU-accelerated, enabling millions of off-target predictions per second, and every match is scored with a documented similarity formula and Gumbel-distribution e-value for interpretability.
Target Audience
Primary customers are pharmaceutical companies, biotechnology firms, and research institutes engaged in drug discovery, off-target safety screening, enzyme engineering, and biocatalysis, including those working on virology and green chemistry applications.
Features
- Catalophore™ point-cloud cavity detection that maps every binding site as a hyperdimensional fingerprint with 15+ property channels, including hydrophobicity, electrostatics, desolvation, H-bond donor/acceptor, aromatic and cation-pi interactions, and metal coordination.
- Proteome-wide cavity search that compares query sites against 10.2 million pre-detected binding pockets from 231,000 PDB structures, enabling discovery beyond sequence or fold similarity.
- GPU-accelerated inference delivering up to five million off-target predictions per second, with AI assistance for structure prediction, paper extraction, and natural-language navigation.
- Catalophore Pro workbench that unifies structures, sequences, cavities, ligands, projects, and experiments in one searchable interface with list, card, and image views.
- CavitOmiX cloud copilot for ranked off-target lists with structural evidence, and a PyMOL plugin for in-viewer cavity detection and matching.
- Per-property weight customization and documented similarity scoring with Gumbel-distribution e-values, ensuring results are defensible for IP, regulatory, and VP-level review.